Clinical course of 771 patients with bilateral breast cancer: Characteristics associated with overall and recurrence-free survival

Clinical Breast Cancer

Volumn 7, Issue 11, 2007, Pages 867-874

  Beinart, Garth ^a   Gonzalez Angulo, Ana M ^a   Broglio, Kristine ^a   Mejia, Jaime ^a   Ruggeri, Anthony ^a   Mininberg, Eric ^a   Hortobagyi, Gabriel N ^a   Valero, Vicente ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Estrogen receptor; Immunohistochemistry; Lymphovascular invasion; Magnetic resonance imaging; Progesterone receptor

Indexed keywords

ANTINEOPLASTIC AGENT; HORMONE RECEPTOR;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BILATERAL CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HISTOLOGY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; MEDICAL RECORD REVIEW; PHYSICAL EXAMINATION; SELF EXAMINATION;

EID: 38049077013     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2007.n.052     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
2. Newman LA, Sahin AA, Cunningham JE, et al. A case-control study of unilateral and bilateral breast carcinoma patients. Cancer 2001; 91:1845-53.
3. Rosen PP, Groshen S, Kinne DW, et al. Contralateral breast carcinoma: an assessment of risk and prognosis in stage I (T1N0M0) and stage II (T1N1M0) patients with 20-year follow-up. Surgery 1989; 106:904-10.
4. Chaudary MA, Millis RR, Hoskins EO, et al. Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg 1984; 71:711-4.
5. Robinson E, Rennert G, Rennert HS, et al. Survival of first and second primary breast cancer. Cancer 1993; 71:172-6.
6. Mertens WC, Hubert V, Makari-Judson G. Contralateral breast cancer: factors associated with stage and size at presentation. Breast J 2004; 10:304-12.
7. Howe HL, Weinstein R, Alvi R, et al. Women with multiple primary breast cancers diagnosed within a five year period, 1994-1998. Breast Cancer Res Treat 2005; 90:223-32.
8. Healey EA, Cook EF, Orav EJ, et al. Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol 1993; 11:1545-52.
9. Heron DE, Komarnicky LT, Hyslop T, et al. Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer 2000; 88:2739-50.
10. Jobsen JJ, van der Palen J, Ong F, et al. Synchronous, bilateral breast cancer: prognostic value and incidence. Breast 2003; 12:83-8.
11. Smith TJ, Davidson NE, Schapira Dy et al. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 1999; 17:1080-2.
12. Rojas MP, Telaro E, Russo A, et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev 2000; (4): CD001768.
13. Dawson LA, Chow E, Goss PE. Evolving perspectives in contralateral breast cancer. Eur J Cancer 1998; 34:2000-9.
14. Shapiro S. Screening: assessment of current studies. Cancer 1994; 74(1 suppl):231-8.
15. Luckmann R. Magnetic resonance imaging was more sensitive than mammography for detecting breast cancer in high-risk women. ACP J Club 2005; 142:23.
16. de la Rochefordiere A, Mouret-Fourme E, Asselain B, et al. Metachronous contralateral breast cancer as first event of relapse. Int J Radiat Oncol Biol Phys 1996; 36:615-21.
17. Brenner H, Engelsmann B, Stegmaier C, et al. Clinical epidemiology of bilateral breast cancer. Cancer 1993; 72:3629-35.
18. Fracchia AA, Robinson D, Legaspi A, et al. Survival in bilateral breast cancer. Cancer 1985; 55:1414-21.
19. Carmichael AR, Bendall S, Lockerbie L, et al. The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours. Eur J Surg Oncol 2002; 28:388-91.
20. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex. Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60-2.
21. Li BD, Byskosh A, Molteni A, et al. Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol 1994; 57:71-7.
22. Lower EE, Glass EL, Bradley DA, et al. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005; 90:65-70.
23. Arpino G, Weiss HL, Clark GM, et al. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol 2005; 23:4687-94.
24. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717.
25. Grann VR, Troxel AB, Zojwalla NJ, et al. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 2005; 103:2241-51.
26. Shen Y, Yang Y, Inoue LY, et al. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 2005; 97:1195-203.